Simplifying Risk-Based Monitoring
14 june 2019

Simplifying Risk-Based Monitoring

A few years have elapsed since ICH added the E6 (R2) addendum to its Good Clinical Practice Guidelines. Amongst other things, the revision was made to mandate adoption of quality risk evaluation & management methodologies in clinical trial design, execution and oversight.

We at ClinMed Pharma have a traffic light system where risk is characterised dynamically in red, amber and green from: study design; study protocol requirements; datapoints; site selection; site performance; document management; data quality and CRO and sponsor study governance at all levels. 

We work cross-functionally to create a training data set based on existing knowledge. This knowledge is then embedded in every aspect of study design, planning, execution and oversight. As the study progresses the risk characterisation is proactively reviewed and updated. Any item requiring attention is actioned promptly and comprehensively. The ultimate aim is to execute a programme with operational, scientific, medical, clincial  and data science excellence.        

Contact us at to find out how we are supporting our sponsors with their pivotal (and non-pivotal) programmes.


26 june 2019
About non-verbal communication

After a riveting meeting with a team in Milan who are developing a game changing asset in the parkinsonsdisease space...

25 june 2019
An intriguing meeting with a values-driven organisation

Members of our leadership team after an intriguing meeting with a values-driven organisation that puts patients first.

28 may 2019
World’s first ‘Darwinian’ cancer drug programme aims to deliver step change in cancer treatment

We at Clinmed Pharma were excited when we read this.

27 may 2019
Theresa May’s commitment to diagnosing cancers earlier is great news

This is a topic that is close to our heart as we have just completed a very large international pivotal colorectal cancer clinical trial.